Distal biliary tract carcinoma

Summary

Distal biliary tract carcinoma (MONDO:0003707) is a cancer and 9 clinical trials. Top therapeutic interventions include cisplatin, binimetinib, and cobimetinib. A subtype of extrahepatic bile duct carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	distal biliary tract carcinoma
Mondo ID	MONDO:0003707
DOID	DOID:5923
NCIT	C7109
UMLS	C1333308
MedGen	232133
GARD	0023627
Is cancer (heuristic)	yes

Also known as: carcinoma of distal biliary tract · distal bile duct cancer · distal bile duct carcinoma · extrahepatic (distal) bile duct cancer

Disease family

This is a subtype of extrahepatic bile duct carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma › extrahepatic bile duct carcinoma › distal biliary tract carcinoma

Related subtypes (5): extrahepatic bile duct adenocarcinoma, extrahepatic bile duct leiomyosarcoma, extrahepatic bile duct squamous cell carcinoma, carcinoma of the ampulla of vater, carcinoma in situ of extrahepatic bile duct

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE1	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03768414	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT04941287	PHASE2	ACTIVE_NOT_RECRUITING	Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
NCT05564403	PHASE2	ACTIVE_NOT_RECRUITING	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT01425879	PHASE2	COMPLETED	MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
NCT02042443	PHASE2	COMPLETED	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
NCT04072445	PHASE2	COMPLETED	Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
NCT04491942	PHASE1	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT05285358	PHASE1	RECRUITING	Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
NCT04561453	Not specified	TERMINATED	Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	3
BINIMETINIB	4	1
COBIMETINIB	4	1
GEMCITABINE	4	1
TIPIRACIL HYDROCHLORIDE	4	1
TRAMETINIB	4	1
TRIFLURIDINE	4	1
VARLILUMAB	2	1
ELIMUSERTIB	1	1
CHEMBL5433950	0	1
CHEMBL4538425	0	1